Compare Enveric Biosciences Inc (ENVB) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs General Mills, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while General Mills, Inc. trades at $32.42 (market cap $17.43B). The key difference: General Mills, Inc. is far larger — about 2563.2× Enveric Biosciences Inc's market cap, and General Mills, Inc. pays a 7.49% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and General Mills, Inc. for 106 Days on average.
| ENVB | GIS | |
|---|---|---|
Market Cap | $6.80M | $17.43B |
Volume | 64,867 | 16,554,362 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $49.36 |
52-Week Low | $1.27 | $31.67 |
Typical Hold Time | 14 Days | 106 Days |
Enterprise Value | -$1.49M | $30.61B |
Dividend Yield | — | 7.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
General Mills (GIS) trades at $31.77, down 1.27% on the day, with a bearish technical signal and mixed earnings performance. The stock shows attractive valuation ratios like a P/E of 9.23 and P/S of 0.93, but profitability metrics are weak with a negative net income margin and ROE. Recent news highlights a CEO transition and a 22% stock decline last month amid revenue and profit pressures.
The outlook is cautious; while the dividend yield is appealing and cost-saving initiatives are in place, declining revenue, margin compression, and high debt levels pose significant risks. Analyst consensus is mixed with a $36 price target, but bearish sentiment and competitive pressures suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
